BMO Capital Upgrades Ionis Pharmaceuticals (IONS) to Outperform; To Benefit form Alnylam Failure
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 225.10 -5.61 (2.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $230.71 | 52 Week High | $109.10 | |||
| Open | $227.86 | 52 Week Low | $31.38 | |||
| Day High | $230.84 | P/E | N/A | |||
| Day Low | $224.88 | EPS | $-1.45 | |||
| Volume | 1,181,022 | |||||
| (NASDAQ: IONS) | Delayed: 44.27 -1.13 (2.49%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $45.40 | 52 Week High | $62.68 | |||
| Open | $45.55 | 52 Week Low | $19.59 | |||
| Day High | $45.76 | P/E | N/A | |||
| Day Low | $44.26 | EPS | $0.00 | |||
| Volume | 2,269,837 | |||||
